ARWR - Arrowhead Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.13
+0.21 (+1.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.92
Open17.82
Bid17.70 x 800
Ask19.00 x 3000
Day's Range17.60 - 18.26
52 Week Range5.35 - 22.39
Volume1,961,591
Avg. Volume1,721,921
Market Cap1.708B
Beta (3Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.25
Trade prices are not sourced from all markets
  • Zacks Small Cap Research8 days ago

    ARWR’s 2019 Goals Include Data From Several Studies, Initiation of Ph2 ARO-AAT

    By Brian Marckx, CFA NASDAQ:ARWR READ THE FULL RESEARCH REPORT HERE 2019 Goals Include: Data from HBV, ANG3 and APOC3 (and possibly AMG-890), Begin AAT Ph2 Program  Arrowhead’s (NASDAQ:ARWR) clinical programs ...

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of ARWR earnings conference call or presentation 7-Feb-19 9:30pm GMT

    Q1 2019 Arrowhead Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE8 days ago

    Biotech Stocks Rising

    Below are several biotech companies in the news you should know HENDERSON, NV / ACCESSWIRE / February 12, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences ...

  • Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today
    Motley Fool12 days ago

    Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today

    The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.

  • Arrowhead Pharmaceuticals Inc (ARWR) Q1 2019 Earnings Conference Call Transcript
    Motley Fool12 days ago

    Arrowhead Pharmaceuticals Inc (ARWR) Q1 2019 Earnings Conference Call Transcript

    ARWR earnings call for the period ending December 31, 2018.

  • Associated Press13 days ago

    Arrowhead Research: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Pasadena, California-based company said it had net income of 13 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

  • Business Wire13 days ago

    Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

    - Conference Call and Webcast Today at 4:30 p.m. EST

  • Benzinga13 days ago

    The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...

  • GlobeNewswire20 days ago

    Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Have Insiders Been Selling Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares?
    Simply Wall St.21 days ago

    Have Insiders Been Selling Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • Business Wire27 days ago

    Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3194897. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3194897.

  • 5 Hot Small-Cap Stocks That Are a Bit Too Toasty
    InvestorPlace29 days ago

    5 Hot Small-Cap Stocks That Are a Bit Too Toasty

    Among publicly tradable securities, perhaps none are more enticing than small-capitalization firms, or colloquially, small-cap stocks. Though specific definitions vary, these investments typically describe companies with market values between $300 million and $2 billion. Why would anyone want to risk their money on these speculative offers? The most obvious answer is profitability potential. Larger companies usually enjoy greater resources, and analysts as a collective force have vetted every detail. Not many surprises exist, which means these blue chips provide relatively stable trading dynamics. On the other hand, smaller firms, especially hot small-cap stocks, have an information "blackout." Analyst coverage is limited, if one is even on tap. Moreover, upstart organizations suffer a credibility gap. Almost always, they promise much upfront, but their ability to deliver over the long run remains questionable. InvestorPlace - Stock Market News, Stock Advice & Trading Tips However, this lack of information also represents the greatest strength for small-cap stocks. Like anything in life -- betting on a racehorse or drafting a franchise quarterback -- higher risks can yield higher rewards. In addition, if you're not about to retire, a controlled exposure to hot small-cap stocks is prudent. Unlike their well-capitalized counterparts, smaller firms provide explosive profitability potential over a short time frame. What it would take a Dow Jones blue chip to accomplish in 10 years can be realized within a matter of months, or even weeks. * 7 Dark Horse Stocks You Really Need to Look at for 2019 That said, you want to know when to pull the trigger, and when to call it quits. Here are five small-cap stocks that are on fire, but you shouldn't buy until the time is right: ### Crocs (CROX) Source: Shutterstock Due to its sub-$2 billion market value, Crocs (NASDAQ:CROX) fits within the accepted range of small-cap stocks. Despite my personal styling reservations, Crocs' signature shoes -- the clog-like ones manufactured with holes in them -- have fit well with customers. As a result, CROX stock has absolutely dominated Wall Street. Last year, shares doubled in value. More impressively, Crocs continued to deliver the goods throughout 2018, and carried positive momentum into the current year. So far this month, CROX has gained 8.6%. At the same time, every good thing must come to an end. CROX stock has gone too far too fast. Earlier in January, the shoemaker received a price-target upgrade from $25 to $31. Right now, we're very close to meeting this forecast. I can dive into further details, but in this case, common sense provides the best argument. Without question, CROX is one of the most intriguing hot small-cap stocks. But right now, it's overheated. ### Fossil Group (FOSL) Source: Joe King via Flickr (Modified) Famous for its stylish but accessible wristwatches, Fossil Group (NASDAQ:FOSL) has previously generated envious returns. That's not surprising considering its $800-plus million market cap. But last year, the watchmaker suffered a schizophrenic episode. In the first half of 2018, FOSL stock skyrocketed nearly 244%. But poor revenue guidance sparked a rapid deterioration in sentiment, with the second half witnessing a 41% drop. Yet Fossil Group appears to have once again won over investors. Since Christmas Eve, shares have jumped nearly 27%. Should speculators trust FOSL stock? While shares have once again entered the realm of hot small-cap stocks, a major headwind is competition. We know that Fossil has significant smartwatch cred as evidenced by Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) recent deal with them. However, smartwatches aren't unique and it's a crowded sector. * 7 Retail Stocks to Buy for the Rise of Menswear With the troubles Apple (NASDAQ:AAPL) has endured selling its once-unassailable products, it's a good idea to let Fossil cool off. ### Boyd Gaming (BYD) Source: Ace Via on Flickr With a market cap of $3 billion, gaming and hospitality outfit Boyd Gaming (NYSE:BYD) is one of the more well-resourced small-cap stocks. Given its exposure to the "vice" industry, BYD stock has natural appeal for speculators. When the economy is chugging along, consumer confidence increases, potentially resulting in higher gambling revenues. But if economic conditions deteriorate, the euphemistically-labeled "hospitality" industry offers escapism. Therefore in theory, BYD stock should witness sustained growth. Unfortunately, the second half of 2018 proved otherwise. After questions about economic stability surfaced, Boyd tumbled badly, shedding nearly 39%. However, Santa put BYD in his "nice" list. Since Christmas Eve, shares have blown up in a good way, delivering 39% returns for embattled shareholders. So is this evidence of a turnaround? I'm hesitant. Recent events like the unprecedented government shutdown have demonstrated that we're not walking on sound territory. As such, I'd wait before diving into a company so levered to consumer sentiment. ### H&E Equipment Services (HEES) Source: Daniel X O'Neil via Flickr Among hot small-cap stocks, H&E Equipment Services (NASDAQ:HEES) enjoyed a memorable run following President Donald Trump's electoral victory. A day after the historic but contentious election, HEES stock jumped nearly 18%. It's easy to see why speculators loved H&E Equipment Services. The former real-estate mogul promised big plans for his administration, chief among them the border wall. Additionally, the President has espoused a roll-up-your sleeves, "git r done" attitude. Such powerful support from the top naturally boosted HEES stock. But last November, the Democrats secured a critical victory in the midterm elections, winning a House majority. As we're witnessing with the ongoing government shutdown and associated negotiations (ie. finger pointing), Trump is unused to direct resistance. That puts H&E Equipment in a tough position. * 7 Stocks to Buy as the Dollar Weakens Moreover, we're not seeing any political headway. As it stands, we have a stubborn president and an unreasonable opposition party. So despite its massive leap forward in January, you should wait for the likely cool-off phase. ### Arrowhead Pharmaceuticals (ARWR) Source: Shutterstock Similar to other small-cap stocks, Arrowhead Pharmaceuticals (NASDAQ:ARWR) had a split personality in 2018. During the first half, ARWR stock shot into low-earth orbit, profiting speculators nearly 269%. But in the second half, Arrowhead didn't really move the needle, eventually losing more than 9%. However, recent market data suggests that ARWR stock is back to its winning form. So far this month, shares are up over 19%. Is now the time to jump aboard one of the most intriguing hot small-cap stocks? On one hand, I really love the company's biotech cred. Arrowhead specializes in RNA interference, or RNAi. This describes the natural mechanism in which living cells suppress a specific gene's activities. ARWR leverages this mechanism to help combat certain debilitating diseases. But on the flip side, meeting clinical requirements is always a tough business. Moreover, insiders have been dumping their shares since 2015. I think the wiser approach is to hold off and wait. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Growth Stocks for the Return of the Bull * The 10 Best Index Funds to Buy and Hold * 10 Lithium Stocks to Buy Despite the Market's Irrationality Compare Brokers The post 5 Hot Small-Cap Stocks That Are a Bit Too Toasty appeared first on InvestorPlace.

  • Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018
    Motley Foollast month

    Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

    A reversal of fortunes made last year one for the record books.

  • Business Wirelast month

    Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

    Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases.

  • Business Wirelast month

    Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

    Arrowhead Pharmaceuticals Inc. today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III being developed for the treatment of hypertriglyceridemia.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ARWR earnings conference call or presentation 11-Dec-18 9:30pm GMT

    Q4 2018 Arrowhead Pharmaceuticals Inc Earnings Call

  • Arrowhead Research Corp (ARWR): Hedge Funds Are Snapping Up
    Insider Monkey2 months ago

    Arrowhead Research Corp (ARWR): Hedge Funds Are Snapping Up

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

  • Business Wire2 months ago

    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 47,000 shares of common stock. The strike price of options is set at an exercise price per share of $13.66, the last reported closing price of the Company's common stock on December 10, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of one new employee, anticipated to be within 60 days of the date of the approval.

  • Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
    Market Realist2 months ago

    Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

    On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.

  • Why Arrowhead Pharmaceuticals Surged 11% Higher Today
    Motley Fool2 months ago

    Why Arrowhead Pharmaceuticals Surged 11% Higher Today

    The company updated investors on its financial performance, and on its progress developing RNAi therapies.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...

  • Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript

    ARWR earnings call for the period ending September 30, 2018.

  • Business Wire2 months ago

    Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

    Conference Call and Webcast Today at 4:30 p.m. EST

  • Benzinga2 months ago

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...